peptides for muscular dystrophy muscle-homing peptide - Duchennemuscular dystrophy PepGen's novel therapeutic candidate, PGN-EDO51 Peptides for Muscular Dystrophy: A New Frontier in Treatment

Muscular dystrophycauses The landscape of muscular dystrophy treatment is continually evolving, with researchers exploring innovative therapeutic avenues. Among the most promising are peptides, small molecules that are showing significant potential in addressing the underlying causes and symptoms of various forms of muscular dystrophy. This article delves into the current research and applications of peptides in the fight against this debilitating group of genetic disorders.

Understanding Muscular Dystrophy and the Role of Peptides

Muscular dystrophies are a group of inherited diseases characterized by progressive muscle weakness and degeneration. While the specific genetic mutations vary, the common outcome is a loss of functional muscle tissue.2025年8月12日—They usedthe peptide DG9to enhance cellular uptake of a DNA-like molecule called a morpholino that targets exon 44. They then collaborated ... For conditions like Duchenne muscular dystrophy (DMD), caused by mutations in the DMD gene leading to a lack of dystrophin protein, the absence of this crucial structural component results in severe muscle damage and loss.

Peptides are emerging as a powerful tool for several reasons. Their small size allows for easier cellular penetration, and their specific binding capabilities can be harnessed for targeted drug delivery. This is particularly crucial for muscular dystrophy, where getting therapeutic agents to the affected muscle cells efficiently has been a significant challenge作者：X Li·2025·被引用次数：6—In this review, we categorise targeting methods into four types:peptides, antibodies, small molecules and aptamers..

Targeted Delivery and Enhanced Treatment Efficacy

One of the key areas where peptides are making a significant impact is in improving the delivery of existing or experimental therapies. This is often achieved through the development of muscle homing peptidesSerum Peptide Profiles of Duchenne Muscular Dystrophy .... These peptides are designed to specifically bind to receptors on muscle cells, acting like a molecular "address label" to direct therapeutic payloads.

For example, research highlights the use of muscle homing peptides conjugated to ASOs (antisense oligonucleotides). ASOs are a type of molecule used in exon skipping, a therapeutic approach for DMD aimed at restoring the reading frame of the DMD gene. By attaching muscle homing peptides to these ASOs, researchers can enhance their uptake into muscle tissue.DG9 peptide restores muscle function Studies have shown that muscle-homing peptide alone can improve the delivery of antisense oligonucleotides to muscles without significant toxicityIdentification of a novel muscle targeting peptide in mdx mice..

A notable example is the development of DG9 peptide.2025年8月10日—PDF | The accuracy of Mass Spectrometry (MS)-based analysis ofpeptidesin complex biological mixtures improves upon using high resolution. This peptide has demonstrated the ability to enhance cellular uptake of molecules like morpholinos, which are used to target specific exons in the DMD gene.Researchers build on a breakthrough in treating muscular ... In preclinical studies, DG9 peptide has been shown to boost the delivery of exon-skipping therapy, particularly to the heart – a critical area affected in DMD.2022年4月22日—The study states that theDG9 peptidewas modified, which decreased its antisense activity but improved its viability and safety (2). “A balance ... The modification of the DG9 peptide has also been explored to improve its viability and safety profileIdeally, amuscle-targetingpeptideshould (1) bind with high affinity to amuscle-specific receptor, (2) disrupt binding to the natural AAV receptor/ co- ....

Furthermore, CAR Peptide Targets Muscular Dystrophy Lesions in Skeletal Muscle. This peptide was initially identified for its ability to target lesions within the skeletal muscle, offering a direct approach to delivering therapeutic agents to damaged areas.

Restoring Dystrophin and Other Therapeutic Strategies

Beyond delivery enhancement, peptides are also being investigated for their direct therapeutic potential or as components of more complex treatment strategies.2012年4月30日—Isotopically-resolvedpeptideprofiles were acquired on a Matrix-Assisted. Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) mass ...

* Dystrophin Restoration: Early research with peptide-morpholino conjugates, such as PPMO, demonstrated promising results in restoring dystrophin levels in mdx mice (a model for DMD). These conjugates were able to restore dystrophin in both skeletal and cardiac muscles to significant percentages of normal levels. Another approach involves Pip6a-PMO, which has successfully restored low levels of dystrophin throughout the ventricles of mdx miceSerum Peptide Profiles of Duchenne Muscular Dystrophy ....

* Exon Skipping: As mentioned, exon skipping is a well-researched therapeutic strategy for DMDHas anyone thought about or tried peptide therapy? I was specifically thinking of some roles in muscle preservation and regeneration for LGMD.. Peptide-conjugated antisense oligonucleotides, including PPMOs, demonstrate effective exon skipping and prolonged dystrophin restoration. The development of optimized MIF targeting peptides is another strategy aimed at enhancing the uptake of therapeutic oligonucleotides.

* Specific Peptide Applications:

* The Cp10 peptide (also known as CyPep10) has been utilized in conjunction with ASOs to improve exon skipping.作者：E Sasaki·2021·被引用次数：14—A2G80-LSP-Lip can function as a muscle-targeting liposome for DMD via systemic administration, andmay be a useful tool for DMD treatment.

* Extracellular matrix-derived peptides, such as laminin-111 derivatives, are being explored for their potential in treating DMD, often in conjunction with polymeric particles.

* Recombinant MG53 protein, a therapeutic agent that modulates cell membrane repair, is also being investigated for its role in muscular dystrophy treatment.

Emerging and Future Directions

The field is continuously advancing, with new peptides and strategies being identified. In vivo phage display is a powerful technique being used to identify novel muscle-homing peptides for DMD.作者：S Yao·2021·被引用次数：69—2020 FDA TIDES (peptides and oligonucleotides) ...Recombinant MG53 protein modulates therapeutic cell membrane repairin treatment of muscular dystrophy. This approach has led to the discovery of peptides that can target specific muscle tissues, paving the way for more effective drug delivery systemsa promising therapeutic for Duchenne muscular dystrophy.

For DMD, several antisense oligonucleotide (ASO) therapies, including eteplirsen, golodirsen, casimersen, and viltolarsen, are already FDA-approved.Effective Dystrophin Restoration by a Novel Muscle ... The continued development of peptide-based delivery systems aims to further improve the efficacy and accessibility of these and future gene-targeted therapies, making them a useful tool for DMD treatment作者：SMG Jirka·2018·被引用次数：34—Exon skipping is a therapeutic approach for DMD. It employs antisense oligonucleotides (AONs) to restore the disrupted open reading frame, ....

Researchers are also investigating peptides derived from the extracellular matrix, like extracellular matrix-derived peptides (e.g.作者：S Yao·2021·被引用次数：69—2020 FDA TIDES (peptides and oligonucleotides) ...Recombinant MG53 protein modulates therapeutic cell membrane repairin treatment of muscular dystrophy., laminin-111 derivatives), for their therapeutic potential作者：SMG Jirka·2018·被引用次数：34—Exon skipping is a therapeutic approach for DMD. It employs antisense oligonucleotides (AONs) to restore the disrupted open reading frame, ....

The exploration of peptide therapy is not limited to DMD.Development of DG9 peptide-conjugated single- and multi- ... For conditions like Limb-Girdle Muscular Dystrophy (LGMD), the potential roles of peptides in muscle preservation and regeneration are being considered作者：JR Mendell·2010·被引用次数：818—Three pools of 40 overlapping syntheticpeptides(designated MDP1, MDP2, and MDP3) that spanned the entire mini-dystrophin sequence were used to ....

Conclusion

The application of peptides in the treatment of muscular dystrophy represents a significant and exciting area of biomedical research. From enhancing the delivery of gene therapies like exon skipping to directly addressing muscular dystrophy lesions, these small molecules offer a versatile platform for therapeutic innovation.2025年8月12日—They usedthe peptide DG9to enhance cellular uptake of a DNA-like molecule called a morpholino that targets exon 44. They then collaborated ... While challenges remain, the ongoing research and development, including the exploration of DG9 peptide, CAR Peptide Targets Muscular Dystrophy Lesions in Skeletal Muscle, and muscle-homing peptides conjugated to ASOs, offer substantial hope for improved outcomes and a better quality of life for individuals affected by muscular dystrophies. The continuous pursuit of novel peptides and their strategic integration into treatment plans underscore the dynamic progress in understanding and combating these complex genetic disordersDG9 peptide restores muscle function.